Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to '35a Social Code Book V Dossierbewertung A22-32 Version 1.0 Brivaracetam (Epilepsie bei Kindern von ≥ 2 bis < 4 Jahren) 18.05.2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) - 3 - 2 Nutzenbewertung 2.1 Kurzfassung der Nutzenbewertung Hintergrund Der Gemeinsame Bundesausschuss
guidelines for its role in emergency settings.564.2.2 Magnetic resonance imaging Magnetic resonance imaging is the imaging modality of choice and should be performed in all patients with epilepsy except children with genetic generalised epilepsy and childhood epilepsy with centrotemporal spikes (CECTS) who respond to drug treatment (see Table 1).42,56 Routine MRI using simple standard Epilepsies in children and young people: Investigative procedures and management Epilepsies in children and young people: investigative procedures and managementA national clinical guidelineMay 2021SIGN159Key to evidence statements and recommendationsLevels of evidence1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias1+ Well-conducted meta
Association between exposure to antibiotics during pregnancy or early infancy and risk of autism spectrum disorder, intellectual disorder, language disorder, and epilepsy in children: population based cohort study. To evaluate the association between antibiotic use during pregnancy or early infancy and the risk of neurodevelopmental disorders in children. Nationwide population based cohort study and sibling analysis. Korea's National Health Insurance Service mother-child linked database, 2008-21. All children live born between 2009 and 2020, followed up until 2021 to compare those with and without antibiotic exposure during pregnancy or early infancy (first six months of life). Autism spectrum disorder, intellectual disorder, language disorder, and epilepsy in children. After 1:1 propensity score
Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study. Gain-of-function (GoF) variants in KCNT1 encoding for potassium channels are associated with different epilepsy phenotypes, including epilepsy of infancy with migrating focal seizures (EIMFS), other early infantile developmental and epileptic encephalopathies, and focal epilepsy
Circumstances surrounding sudden unexpected death in epilepsy in children: A national case series. This study was undertaken to understand the circumstances surrounding pediatric sudden unexpected death in epilepsy (SUDEP) and identify clinical factors that may be associated with SUDEP in childhood. A retrospective case series was conducted. Pediatric SUDEP cases were collected across Canada
Deep brain stimulation of the centromedian nucleus for drug-resistant epilepsy in children: Quality-of-life and functional outcomes from the CHILD-DBS registry. Deep brain stimulation of the centromedian nucleus of the thalamus (CM-DBS) is an investigational, off-label treatment for drug-resistant epilepsy (DRE) in children. Although emerging evidence supports its safety and efficacy for select
Diagnosis and prognosis of serum Fut8 for epilepsy and refractory epilepsy in children. With adequate serum concentration of antiepileptic drugs, the epilepsy symptoms in many patients still cannot be controlled well. The alteration of glycosyltransferase has obvious influence on the pathogenesis of epilepsy. In this study, we focus on the diagnostic and prognostic value of fucosyltransferase 8
Whole-cycle management of women with epilepsy of child-bearing age: ontology construction and application. The effective management of epilepsy in women of child-bearing age necessitates a concerted effort from multidisciplinary teams. Nevertheless, there exists an inadequacy in the seamless exchange of knowledge among healthcare providers within this context. Consequently, it is imperative to enhance the availability of informatics resources and the development of decision support tools to address this issue comprehensively. The development of the Women with Epilepsy of Child-Bearing Age Ontology (WWECA) adhered to established ontology construction principles. The ontology's scope and universal terminology were initially established by the development team and subsequently subjected
Prenatal Exposure to Antiseizure Medications and Risk of Epilepsy in Children of Mothers With Epilepsy. Use of valproate and certain other antiseizure medications (ASMs) in pregnancy is associated with abnormal fetal brain development with potential long-term implications for the child. To examine whether use of valproate and other ASMs in pregnancy among mothers with epilepsy is associated , and sibling analyses. This cohort study included 38 663 children of mothers with epilepsy (19 854 [51.4%] boys). Children were followed up from birth; the mean length of follow-up was 7.2 years (range 0-22 years). Compared with 22 207 children of mothers not using an ASM in pregnancy, increased risks of epilepsy in children of mothers who used valproate in pregnancy (monotherapy: AHR, 2.18; 95% CI, 1.70
Predictors of drug-resistant epilepsy in childhood epilepsy syndromes: A subgroup analysis from a prospective cohort study. Previous studies assessing factors associated with drug-resistant epilepsy (DRE) were constrained by their amalgamation of all epilepsy syndromes in their analyses and the absence of uniform criteria for defining DRE. Our objective was to identify predictors of DRE among
[Related factors of acute symptomatic seizures and epilepsy in children with myelin oligodendrocyte glycoprotein antibody-associated disease]. To investigate the risk factors of acute symptomatic seizures (ASS) and epilepsy in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). A ambispective cohort study was used including 74 children with MOGAD who were
Electrographic Seizures and Predictors of Epilepsy after Pediatric Arteriovenous Malformation Rupture. To assess clinical and electroencephalogram (EEG) predictors of epilepsy and to describe the percentage of electrographic seizures (ES) and development of epilepsy among patients with spontaneous intracerebral hemorrhage (ICH) due to arteriovenous malformation (AVM) rupture. Retrospective
[(18)F]FDG PET for mapping the cerebral glucose metabolic characteristics of drug-sensitive and drug-resistant epilepsy in pediatric patients. This study aimed to investigate [F]fluorodeoxyglucose positron emission tomography ([F]FDG PET) mapping for cerebral glucose metabolism in drug-sensitive and drug-resistant pediatric epilepsy patients. This retrospective study enrolled 40 patients and 25
A new perspective on drug-resistant epilepsy in children with focal cortical dysplasia type 1: From challenge to favorable outcome. We comprehensively characterized a large pediatric cohort with focal cortical dysplasia (FCD) type 1 to expand the phenotypic spectrum and to identify predictors of postsurgical outcomes. We included pediatric patients with histopathological diagnosis of isolated
Vigabatrin (Kigabeq) - epilepsy in children between 1 month and 7 years of age Kigabeq | European Medicines Agency Skip to main content Search Search Menu * Medicines * Human regulatory Human regulatory * Overview * Research and development * Marketing authorisation * Post-authorisation * Herbal products * Veterinary regulatory Veterinary regulatory * Assessment historyAuthorised This medicine is authorised for use in the European Union. OverviewKigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age. It is used in the following ways: * on its own to treat infantile spasms (West syndrome), a rare epilepsy disorder that starts at a very young age, usually in the first few months of life; * together with other medicines
Therapeutical impacts of transcranial direct current stimulation on drug-resistant epilepsy in pediatric patients: A double-blind parallel-group randomized clinical trial. Drug-resistant epilepsy is a challenging problem in pediatrics. Transcranial direct current stimulation (TDCS) is a non-invasive neurostimulation technique suggested as a promising method for treating epilepsy. This study aims to evaluate the efficacy of TDCS in focal epilepsy in children with drug-resistant epilepsy. We conducted a randomized sham-controlled study with 18 subjects between 6 and 16 years of age, divided equally into two groups. TDCS was performed in 20-minute daily stimulation protocol for five days for both groups. The current intensity was one mA for the first three days, increasing to 1.5 mA on day four and 2
Sudden unexpected death in epilepsy in children. Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality in children and adults living with epilepsy. The incidence of SUDEP is comparable in both children and adults; it is approximately 1.2 per 1000 person years. The pathophysiology of SUDEP is not well understood but may involve mechanisms such as cerebral
Epilepsy in childhood and school performance: a nation-wide cohort study. Childhood epilepsy has been linked to poor academic performance, but large-scale studies are lacking. In this nation-wide study of school-aged children, we examined the association between childhood epilepsy and school performance in standardized tests according to phenotypic and treatment-related characteristics. We
[Analysis of the efficacy and influencing factors of sodium channel blockers in the treatment of focal epilepsy in infants under 6 months of age]. To analyze the efficacy and safety of the sodium channel blockers (SCB) antiseizure medication in the treatment of focal epilepsy in infants under 6 months of age. This was a case series study. Infants with focal epilepsy with onset within 6 months discontinuing oxcarbazepine and switching to lacosamide, and 7 cases of electrocardiogram abnormalities, which improved after withdrawing oxcarbazepine and changing to lacosamide in 1 case. SCB are effective and tolerable in the treatment of focal epilepsy in infants under 6 months of age, with better efficacy in patients with genetic variants of the sodium or potassium channel, focal seizures only